TABLE 2.
Univariate and multivariate analyses in primary and validation cohorts
| Univariate Cox analysis | Multivariate Cox analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Primary cohort | Validation cohort | Primary cohort | Validation cohort | |||||
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| TNM Stage | ||||||||
| I | 1 | 1 | 1 | 1 | ||||
| II | 1.96 (1.18–3.26) | <0.01 | 3.54 (1.29–9.66) | 0.01 | 1.73 (1.00–2.98) | <0.05 | 2.32 (0.84–6.39) | 0.10 |
| III | 4.45 (2.73–7.24) | <0.01 | 11.3 (4.19–30.7) | <0.01 | 3.45 (2.02–5.90) | <0.01 | 6.69 (2.44–18.4) | <0.01 |
| IV | 8.60 (4.14–17.9) | <0.01 | 48.9 (16.7–142) | <0.01 | 4.15 (1.86–9.29) | <0.01 | 39.82 (13.2–120) | <0.01 |
| Sex | ||||||||
| Male | 1 | 1 | — | — | ||||
| Female | 0.80 (0.62–1.02) | 0.08 | 1.04 (0.81–1.33) | 0.75 | — | — | ||
| Age | 1.03 (1.02–1.05) | <0.01 | 1.02 (1.01–1.03) | <0.01 | 1.04 (1.02–1.05) | <0.01 | 1.03 (1.02–1.04) | <0.01 |
| Location | ||||||||
| Colon | 1 | 1 | — | — | ||||
| Rectum | 1.05 (0.83–1.34) | 0.66 | 1.17 (0.91–1.49) | 0.22 | — | — | ||
| CEA | ||||||||
| Normal | 1 | 1 | 1 | — | ||||
| Abnormal | 2.63 (2.06–3.36) | <0.01 | 1.51 (1.17–1.94) | <0.01 | 1.94 (1.51–2.50) | <0.01 | — | |
| Grade | ||||||||
| Low | 1 | 1 | — | 1 | ||||
| High | 1.82 (1.27–2.59) | <0.01 | 1.69 (1.28–2.23) | <0.01 | — | 1.58 (1.19–2.10) | <0.01 | |
| MSI status | ||||||||
| MSI | 1 | 1 | — | — | ||||
| MSS | 1.67 (1.00–2.79) | 0.049 | 1.73 (0.53–5.67) | 0.4 | — | — | ||
| DR | ||||||||
| Mature | 1 | 1 | 1 | 1 | ||||
| Middle | 1.62 (1.23–2.13) | <0.01 | 2.09 (1.53–2.87) | <0.01 | 1.32 (0.98–1.76) | 0.06 | 1.92 (1.38–2.65) | <0.01 |
| Immature | 2.73 (2.00–3.71) | <0.01 | 3.01 (2.24–4.04) | <0.01 | 1.84 (1.32–2.56) | <0.01 | 2.66 (1.94–3.64) | <0.01 |
NOTE: CEA was analyzed on the basis of 2,112 available patients. MSI status was available in 1,104 patients and grade was analyzed on the basis of 2,165 available patients. Others were analyzed on the basis of whole patients.
Abbreviations: 95%CI, 95% confidence interval; CEA, carcinoembryonic antigen; ; DR, desmoplastic reaction; HR, hazard ratio; MSI, microsatellite instability; MSS, microsatellite stability; TNM, tumor-node-metastasis.